Viral Clearance Market Segmentation:
Application Segment Analysis
The recombinant proteins segment of the viral clearance market is projected to hold a dominant 36% revenue share by the end of 2037. The growth is driven by the increase in biosimilars and therapeutic proteins that are in production for chronic diseases such as cancer and diabetes. The Centers for Disease Control reported an estimated 1.5 million new cancer cases in the U.S. in 2023. This has resulted in substantial increases in biologics that require viral clearance. In 2023, the FDA approved 54 biologics, including vaccines, of which 76% were comprised of recombinant proteins due to favorable outcomes and shorter development cycles. The global burden of chronic disease is also on the rise, with estimates made by the World Health Organization that 17.3 million people died in 2023 from cardiovascular disease.
Method Segment Analysis
The viral clearance segment is poised to account for a 41% revenue share in the market due to its accuracy and regulation. With over 45 new drug approvals in 2021, the FDA consistently applies strict guidelines to ensure a strong viral clearance path. In 2023, NIH's biomedical research funding of USD 44 billion encourages R&D in nanofiltration and shows how to be more efficient. The increasing biopharma research and development, with 7% of global specialty drug spending occurring in 2020, is contributing to the growth of this segment.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Subsegment |
|
Application |
|
|
Method |
|
|
End-User |
|
